• Polyrizon published a press release reporting successful biocompatibility results for NASARIX, supporting plans to advance toward a first-in-human trial.
• All required biological safety tests met predetermined acceptance criteria under ISO 10993-aligned evaluation.
• Long-term systemic toxicity risk assessment indicated substantial safety margins under intended use conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607020732PRIMZONEFULLFEED9756131) on July 02, 2026, and is solely responsible for the information contained therein.